Dementia
Not recommended
Lion's mane marketing leans on fear of dementia: «protects the brain from Alzheimer's», «restores neurons», «natural memantine». The Mori 2009 RCT is the only available double-blind trial, and it enrolled 30 Japanese adults with MCI, not Alzheimer's disease. The 1.3-point HDS-R effect after 16 weeks with return to baseline after stopping is a weak symptomatic signal, not disease modification. RCTs in patients with established Alzheimer's, vascular, or frontotemporal dementia are absent. NG97 recommends cholinesterase inhibitors (donepezil, rivastigmine, galantamine) in mild-moderate Alzheimer's and memantine in moderate-severe disease; primary prevention runs through blood-pressure, diabetes, and lipid control, smoking cessation, exercise, a Mediterranean diet, hearing-loss management, and social engagement. The Dementia Fact Sheet 2023 and the Alzheimer's Association point out: no «brain health» supplement modifies the course of dementia, and «natural memantine» marketing is unsupported by clinical data. A real risk of lion's mane in suspected dementia is delaying neurologic or geriatric assessment and losing the window when approved drugs still work. If lion's mane was bought for a relative with Alzheimer's, consider seeking a second opinion – NICE NG97 dementia management does not include mushroom supplements.
Sources
- Phytother Res (Mori et al.): Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial (2009)
- NICE: Dementia: assessment, management and support for people living with dementia and their carers (NG97) (2018)
- WHO: Dementia – key facts and risk reduction (2023)
- Alzheimer's Association: Alternative Treatments – evidence and risks for dementia (2024)